PD1
HPV
PD-1
head and neck cancer
survival
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
03 Nov 2022
03 Nov 2022
Historique:
received:
07
10
2022
revised:
25
10
2022
accepted:
01
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Head and neck squamous cell carcinomas (HNSCCs) belong to a group of diverse tumors, which can be induced by infection with human papillomavirus (HPV) or tobacco and alcohol consumption. The viral etiology of HNSCC relates to better clinical outcomes reflecting a different immune system response. Here, we retrospectively analyzed 97 tissue samples from oral and oropharyngeal carcinomas associated and non-associated with HPV infection using multispectral fluorescent immunohistochemistry. To evaluate the immune cell infiltration in tumor and stroma compartments, we designed four panels of four to five antibodies. We detected more T lymphocytes in the stroma, compared to the tumor parenchyma. In HPV positive (HPV
Identifiants
pubmed: 36359314
pii: biomedicines10112794
doi: 10.3390/biomedicines10112794
pmc: PMC9687997
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Czech Health Research Council
ID : 17-28055A
Organisme : the Ministry of Education, Youth and Sports of the Czech Republic
ID : CZ.02.1.01/0.0/0.0/16_019/0000785
Organisme : European Union - Next Generation EU
ID : Project No. LX22NPO5103
Organisme : Charles University
ID : SVV 260568
Références
Int J Cancer. 2011 Jul 1;129(1):101-10
pubmed: 21190188
Eur J Cancer. 2013 Jul;49(11):2522-30
pubmed: 23571147
Cancer Immunol Immunother. 2021 May;70(5):1227-1237
pubmed: 33125511
Oncotarget. 2017 Feb 28;8(9):14416-14427
pubmed: 28122336
Cancer Res. 2017 Nov 15;77(22):6353-6364
pubmed: 28904066
Br J Cancer. 2015 Sep 15;113(6):886-93
pubmed: 26313665
Sci Rep. 2021 Aug 9;11(1):16134
pubmed: 34373557
Viruses. 2019 Oct 09;11(10):
pubmed: 31600915
Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):523-532
pubmed: 28187033
Cancer Immunol Immunother. 2020 Apr;69(4):581-591
pubmed: 31980916
JAMA Otolaryngol Head Neck Surg. 2019 Nov 01;145(11):1012-1019
pubmed: 31486841
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
Cancer Immunol Immunother. 2020 Mar;69(3):465-476
pubmed: 31950224
PLoS One. 2020 Nov 19;15(11):e0242058
pubmed: 33211709
J Pathol. 2017 Nov;243(3):354-365
pubmed: 28771750
Biomed Res Int. 2014;2014:303929
pubmed: 24864233
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Br J Cancer. 2020 Sep;123(6):932-941
pubmed: 32616847
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Int J Cancer. 2013 Oct 15;133(8):1832-9
pubmed: 23564321
PLoS One. 2012;7(6):e38711
pubmed: 22701698
J Med Virol. 2009 May;81(5):878-87
pubmed: 19319944
Cancer Immunol Res. 2018 Mar;6(3):295-304
pubmed: 29378694
Oncotarget. 2017 Jul 4;8(27):44418-44433
pubmed: 28574843
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Oral Oncol. 2015 Jan;51(1):90-5
pubmed: 25283344
Int J Cancer. 2016 Jan 15;138(2):386-95
pubmed: 26239888
Clin Cancer Res. 2006 Jan 15;12(2):465-72
pubmed: 16428488
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668519
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
Clin Cancer Res. 2019 Apr 15;25(8):2442-2449
pubmed: 30617133
J Biomed Res. 2018 Sep 29;32(5):317-326
pubmed: 28866656
Expert Opin Ther Targets. 2018 Apr;22(4):343-351
pubmed: 29468927
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376
J Oral Pathol Med. 2017 Nov;46(10):972-978
pubmed: 28632936
Blood. 1997 Feb 15;89(4):1376-82
pubmed: 9028961